Femasys’ (FEMY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Femasys (NASDAQ:FEMY) in a report released on Tuesday morning,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($0.84) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Separately, Chardan Capital lowered their price objective on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Femasys Price Performance

Shares of FEMY traded down $0.01 during mid-day trading on Tuesday, hitting $0.97. The company’s stock had a trading volume of 62,503 shares, compared to its average volume of 332,387. The firm has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.15. The stock has a market capitalization of $22.29 million, a price-to-earnings ratio of -1.21 and a beta of -2.83. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 5.93. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. On average, research analysts predict that Femasys will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Femasys stock. CM Management LLC lifted its position in Femasys Inc. (NASDAQ:FEMY) by 6.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 425,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. CM Management LLC owned about 1.91% of Femasys worth $484,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.